Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease

Mouli Pal, Weili Bao, Rikang Wang, Yunfeng Liu, Xiuli An, William B. Mitchell, Cheryl A. Lobo, Caterina Minniti, Patricia A. Shi, Deepa Manwani, Karina Yazdanbakhsh, Hui Zhong

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Red blood cell alloimmunization remains a barrier for safe and effective transfusions in sickle cell disease (SCD), but the associated risk factors remain largely unknown. Intravascular hemolysis, a hallmark of SCD, results in the release of heme with potent immunomodulatory activity, although its effect on SCD humoral response, specifically alloimmunization, remains unclear. Here, we found that cell-free heme suppresses human B-cell plasmablast and plasma cell differentiation by inhibiting the DOCK8/STAT3 signaling pathway, which is critical for B-cell activation, as well as by upregulating heme oxygenase 1 (HO-1) through its enzymatic byproducts, carbon monoxide and biliverdin. Whereas nonalloimmunized SCD B cells were inhibited by exogenous heme, B cells from the alloimmunized group were nonresponsive to heme inhibition and readily differentiated into plasma cells. Consistent with a differential B-cell response to hemolysis, we found elevated B-cell basal levels of DOCK8 and higher HO-1-mediated inhibition of activated B cells in nonalloimmunized compared with alloimmunized SCD patients. To overcome the alloimmunized B-cell heme insensitivity, we screened several heme-binding molecules and identified quinine as a potent inhibitor of B-cell activity, reversing the resistance to heme suppression in alloimmunized patients. B-cell inhibition by quinine occurred only in the presence of heme and through HO-1 induction. Altogether, these data suggest that hemolysis can dampen the humoral B-cell response and that B-cell heme responsiveness maybe a determinant of alloimmunization risk in SCD. By restoring B-cell heme sensitivity, quinine may have therapeutic potential to prevent and inhibit alloimmunization in SCD patients. (Blood. 2021;137(2):269-280).

Original languageEnglish (US)
Pages (from-to)269-280
Number of pages12
JournalBlood
Volume137
Issue number2
DOIs
StatePublished - Jan 14 2021

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease'. Together they form a unique fingerprint.

Cite this